Coreg CR Gets Green Light for Generic Lifeline
Published Date: 5/30/2025
Notice
Summary
The FDA says COREG CR extended-release capsules (10, 20, 40, and 80 mg) weren’t pulled from shelves because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price spikes. If you use or make this medicine, things will keep running smoothly without any sudden changes.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics remain available; no shortages
The FDA determined that COREG CR (carvedilol phosphate) extended‑release capsules — 10 mg, 20 mg, 40 mg, and 80 mg — were not withdrawn from sale for reasons of safety or effectiveness. That means the FDA will continue to allow approval of generic versions, so patients and pharmacies won’t face sudden shortages or price spikes for these strengths.
ANDA approvals will continue for COREG CR
The FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to COREG CR extended‑release capsules (10 mg, 20 mg, 40 mg, 80 mg) and will allow continued approval of ANDAs that meet legal and regulatory requirements. This preserves the pathway for generic manufacturers and applicants to obtain approvals for these products.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
Previous / Next Documents
Previous: 2025-09771 — Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability
The FDA just released its yearly report on how drug and biologics companies are doing with their promised follow-up studies after approval. This report affects companies that make these products and helps everyone see if they’re keeping their promises to keep medicines safe. Check it out online anytime to see the latest updates—no extra cost or waiting needed!
Next: 2025-09773 — Petition for Exemption; Summary of Petition Received; Pyka Inc.
Pyka Inc. asked the FAA to relax some rules so they can test and use their special delivery drones more easily. This change could speed up drone deliveries and help businesses save time and money. If approved, it affects drone operators and customers who want faster, smarter deliveries soon.